Home / Stocks / BIIB

Biogen (BIIB, Biotechnology) Stock Valuation & Fair Value Fairly valued

Biogen (BIIB, Biotechnology) trades at a blended P/E of 15.9, about 3% above its historical normal valuation, with a forward growth estimate of 14.3% and a PEG of 1.12. Analysts' one-year estimates have been hit 73% of the time.

DATA AS OF 2026-08-21
Blended P/E
15.9
Normal P/E
15.5
PEG
1.12
Fwd growth
14.3%
Div yield
0.0%
RSI (14)
58.1
Neutral

The Street vs SeerForecast

Wall Street's mean price target for BIIB is $237.59 across 32 analysts, 9.6% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-10.

Price and rating by weekClose moved +8.0 percent from 2026-06-10 to 2026-08-17, with 0 rating changes over 20 recorded weeks.2026-06-10: Fairly valued, close 194.24 (recalculated)2026-06-14: Fairly valued, close 200.05 (recalculated)2026-06-16: Fairly valued, close 195.61 (recalculated)2026-06-21: Fairly valued, close 196.58 (recalculated)2026-07-02: Fairly valued, close 216.12 (recalculated)2026-07-06: Fairly valued, close 208.46 (recalculated)2026-07-09: Fairly valued, close 198.91 (recalculated)2026-07-12: Fairly valued, close 199.15 (recalculated)2026-07-13: Fairly valued, close 209.03 (recalculated)2026-07-14: Fairly valued, close 191.95 (recalculated)2026-07-20: Fairly valued, close 199.95 (recalculated)2026-07-22: Fairly valued, close 197.74 (recalculated)2026-07-25: Fairly valued, close 202.19 (recalculated)2026-07-27: Fairly valued, close 200.14 (recalculated)2026-07-31: Fairly valued, close 202.95 (recalculated)2026-08-03: Fairly valued, close 202.952026-08-07: Fairly valued, close 207.94 (recalculated)2026-08-10: Fairly valued, close 207.942026-08-14: Fairly valued, close 209.83 (recalculated)2026-08-17: Fairly valued, close 209.831942102026-06-102026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-10P/E 13.0-16%Fairly valued
2026-06-14P/E 13.0-16%Fairly valued
2026-06-16P/E 13.0-16%Fairly valued
2026-06-21P/E 13.0-16%Fairly valued
2026-07-02P/E 14.0-10%Fairly valued
2026-07-06P/E 14.5-7%Fairly valued
2026-07-09P/E 14.5-7%Fairly valued
2026-07-12P/E 13.4-14%Fairly valued
2026-07-13P/E 13.4-14%Fairly valued
2026-07-14P/E 13.4-14%Fairly valued
2026-07-20P/E 14.2-8%Fairly valued
2026-07-22P/E 14.2-8%Fairly valued
2026-07-25P/E 14.8-5%Fairly valued
2026-07-27P/E 14.8-5%Fairly valued
2026-07-31P/E 15.2-2%Fairly valued
2026-08-03P/E 14.9-4%Fairly valued
2026-08-07P/E 15.2-2%Fairly valued
2026-08-10P/E 15.3-1%Fairly valued
2026-08-14P/E 15.6+1%Fairly valued
2026-08-17P/E 15.6+0%Fairly valued
2026-08-21P/E 15.9+3%Fairly valued ← now

Frequently asked questions

Is Biogen stock overvalued?

At a blended P/E of 15.9 versus its historical normal P/E of 15.5, Biogen trades about 3% above its typical valuation, with a PEG of 1.12 on 14.3% forward growth. tickerseer currently rates it fairly valued.

What is Biogen's fair value and PEG?

Biogen trades at a blended P/E of 15.9 against a historical normal P/E of 15.5, a PEG of 1.12, and a forward growth estimate of 14.3%.

Has tickerseer's rating of Biogen changed?

tickerseer's rating has been fairly valued since 2026-06-10.

What is the analyst price target for Biogen?

The mean Wall Street price target for Biogen is $237.59 across 32 analysts, 9.6% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BIIB free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.